Atu-027

N/A

Report date: 2022/01/29 17:59:22
NME

Base Information

Drug NameAtu-027
Drug Alias NameAtu-027
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionSerine/threonine-protein kinase N3 inhibitorsRNA interference
TargetsSerine/threonine-protein kinase N3
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSilence TherapeuticsAtugen AG
China Registration ClassN/A

Develop Information

Active CompaniesSilence Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursHead and Neck NeoplasmsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A